BASIC FACTS
DATE OF LAUNCH
31 MARCH 1993
CATEGORY
EQUITYTYPE
LARGE & MIDCAP
AUM*
Rs.3,798 Crore
BENCHMARK
NIFTY LARGE MIDCAP 250
TOTAL RETURN INDEX
WHAT IT COSTS
NAV*
GROWTH OPTION
Rs.351.62
IDCW
Rs.56.68
MINIMUM INVESTMENT
Rs.5,000
MINIMUM SIP AMOUNT
Rs.150
EXPENSE RATIO*** (%)
2.23
EXIT LOAD
For units in excess of 12% of the investment,1% will be charged for redemption within 90 days.
*AS ON 31 MARCH 2023
**AS ON 11 APRIL 2023
***AS ON 28 FEBRUARY 2023
FUND MANAGER
CHANDRAPRAKASH PADIYAR
4 YEARS, 6 MONTHS
Recent portfolio changes
New Entrants
Gland Pharma, Bandhan Bank.
Complete Exits
SBI Life Insurance Company
Increasing allocation
Aditya Birla Fashion and Retail, Ashok Leyland, Fortis Healthcare, Housing Development Finance Corporation, Reliance Industries, Zee Entertainment Enterprises.
Should you buy?
This fund transitioned from a large cap biased fund (Tata Equity Opportunities) to the new mandate in 2018, around the same time that the fund house also saw an overhaul of its investing philosophy and change in stewardship. The fund manager prefers large, compounding businesses with superior fundamentals along with companies that have potential for rerating owing to upside surprise in earnings growth. Its portfolio size is also leaner than before. The fund manager is comfortable taking large positions in high conviction bets. The fund lagged index and peers by a wide margin in 2021 but came back strongly last year to top the performance charts. The fund needs to deliver on a sustained basis to make it a worthy bet for long term.
(Source: Value Research)
